Metformin and epithelial ovarian cancer therapeutics

Cellular Oncology

Volumn 38, Issue 5, 2015, Pages 365-375

  Patel, Seema ^a   Kumar, Lalit ^b   Singh, Neeta ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b INSTITUTE ROTARY CANCER HOSPITAL   (India)

Author keywords

Apoptosis; Bcl 2; Metformin; Ovarian cancer

Indexed keywords

CARBOPLATIN; METFORMIN; PACLITAXEL; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; BAX PROTEIN, HUMAN; BCL2L1 PROTEIN, HUMAN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X;

APOPTOSIS; ARTICLE; ASCITES FLUID; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER RESISTANCE; CELL CYCLE ARREST; FEMALE; HUMAN; OVARY CARCINOMA; PRIMARY CELL CULTURE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; CELL CYCLE CHECKPOINT; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; DRUG POTENTIATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM; OVARY TUMOR; PATHOLOGY; TUMOR CELL CULTURE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BLOTTING, WESTERN; CARBOPLATIN; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED;

EID: 84944167682     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-015-0235-7     Document Type: Article

References (33)

1. J.R. Chien, G. Aletti, D.A. Bell, G.L. Keeney, V. Shridhar, L.C. Hartmann, Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer. J. Cell. Biochem. 102, 1117–1129 (2007)
2. Y. Li, K. Wang, Y.-Z. Jiang, X.-W. Chang, C.-F. Dai, J. Zheng, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) inhibits human ovarian cancer cell proliferation. Cell. Oncol. 37, 429–437 (2014)
3. M. Momeni, T. Kalir, S. Farag, L. Chuang, D. Fishman, D.E. Burstein, Expression of H1.5 and PLZF in granulosa cell tumors and normal ovarian tissues: a short report. Cell. Oncol. 37, 229–234 (2014)
4. J. Di, T. Duiveman-de Boer, P.L.M. Zusterzeel, C.G. Figdor, L.F.A.G. Massuger, R. Torensma, The stem cell markers Oct4A, Nanog and c-Myc are expressed in ascites cells and tumor tissue of ovarian cancer patients. Cell. Oncol. 36, 363–374 (2013)
5. I.N. Alimova, B. Liu, Z. Fan, S.M. Edgerton, T. Dillon, S.E. Lind, A.D. Thor, Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 8, 909–915 (2009)
6. M. Zakikhani, R. Dowling, I.G. Fantus, N. Sonenberg, M. Pollak, Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 66, 10269–10273 (2006)
7. G. Zhou, R. Myers, Y. Li, Y. Chen, X. Shen, J. Fenyk-Melody, M. Wu, J. Ventre, T. Doebber, N. Fujii, N. Musi, M.F. Hirshman, L.J. Goodyear, D.E. Moller, Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167–1174 (2001)
8. S.L. Bowker, S.R. Majumdar, P. Veugelers, J.A. Johnson, Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29, 254–258 (2006)
9. G.W.D. Landman, N. Kleefstra, K.J.J. van Hateren, K.H. Groenier, R.O.B. Gans, H.J.G. Bilo, Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 33, 322–326 (2010)
10. G. Libby, L.A. Donnelly, P.T. Donnan, D.R. Alessi, A.D. Morris, J.M.M. Evans, New users of metformin are at low risk of incident cancer A cohort study among people with type 2 diabetes. Diabetes Care 32, 1620–1625 (2009)
11. S. Jiralerspong, S.L. Palla, S.H. Giordano, F. Meric-Bernstam, C. Liedtke, C.M. Barnett, L. Hsu, M.-C. Hung, G.N. Hortobagyi, A.M. Gonzalez-Angulo, Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J. Clin. Oncol. 27, 3297–3302 (2009)
12. A. DeCensi, M. Puntoni, P. Goodwin, M. Cazzaniga, A. Gennari, B. Bonanni, S. Gandini, Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev. Res. 3, 1451–1461 (2010)
13. W.H. Gotlieb, J. Saumet, M.-C. Beauchamp, J. Gu, S. Lau, M.N. Pollak, I. Bruchim, In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol. Oncol. 110, 246–250 (2008)
14. R. Rattan, S. Giri, L.C. Hartmann, V. Shridhar, Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J. Cell. Mol. Med. 15, 166–178 (2011)
15. R. Rattan, R.P. Graham, J.L. Maguire, S. Giri, V. Shridhar, Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia 13, 483–491 (2011)
16. C.J. Bailey, R.C. Turner, Metformin. N. Engl. J. Med. 334, 574–579 (1996)
17. K. Mohankumar, S. Pajaniradje, S. Sridharan, V.K. Singh, L. Ronsard, A.C. Banerjea, B.C. Selvanesan, M.S. Coumar, L. Periyasamy, R. Rajagopalan, Apoptosis induction by an analog of curcumin (BDMC-A) in human laryngeal carcinoma cells through intrinsic and extrinsic pathways. Cell. Oncol. 37, 439–454 (2014)
18. V.V. Dhawan, G.V. Joshi, A.S. Jain, Y.P. Nikam, R.P. Gude, R. Mulherkar, M.S. Nagarsenker, Apoptosis induction and anti-cancer activity of LeciPlex formulations. Cell. Oncol. 37, 339–351 (2014)
19. T. Nakaoka, A. Ota, T. Ono, S. Karnan, H. Konishi, A. Furuhashi, Y. Ohmura, Y. Yamada, Y. Hosokawa, Y. Kazaoka, Combined arsenic trioxide-cisplatin treatment enhances apoptosis in oral squamous cell carcinoma cells. Cell. Oncol. 37, 119–129 (2014)
20. O.N. Ikediobi, H. Davies, G. Bignell, S. Edkins, C. Stevens, S. O’Meara, T. Santarius, T. Avis, S. Barthorpe, L. Brackenbury, G. Buck, A. Butler, J. Clements, J. Cole, E. Dicks, S. Forbes, K. Gray, K. Halliday, R. Harrison, K. Hills, J. Hinton, C. Hunter, A. Jenkinson, D. Jones, V. Kosmidou, R. Lugg, A. Menzies, T. Mironenko, A. Parker, J. Perry, K. Raine, D. Richardson, R. Shepherd, A. Small, R. Smith, H. Solomon, P. Stephens, J. Teague, C. Tofts, J. Varian, T. Webb, S. West, S. Widaa, A. Yates, W. Reinhold, J.N. Weinstein, M.R. Stratton, P.A. Futreal, R. Wooster, Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol. Cancer Ther. 5, 2606–2612 (2006)
21. L.D. Dunfield, T.G. Shepherd, M.W. Nachtigal, Primary culture and mRNA analysis of human ovarian cells. Biol. Proced. Online. 4, 55–61 (2002)
22. E.L. Tobinick, The value of drug repositioning in the current pharmaceutical market. Drug News Perspect. 22, 119–125 (2009)
23. C. Campas, Drug repositioning summit: finding new routes to success. Drug News Perspect. 22, 126–128 (2009)
24. I. Ben Sahra, K. Laurent, A. Loubat, S. Giorgetti-Peraldi, P. Colosetti, P. Auberger, J.F. Tanti, Y. Le Marchand-Brustel, F. Bost, The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27, 3576–3586 (2008)
25. M. Buzzai, R.G. Jones, R.K. Amaravadi, J.J. Lum, R.J. DeBerardinis, F. Zhao, B. Viollet, C.B. Thompson, Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 67, 6745–6752 (2007)
26. K. Kisfalvi, G. Eibl, J. Sinnett-Smith, E. Rozengurt, Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res. 69, 6539–6545 (2009)
27. A. Isakovic, L. Harhaji, D. Stevanovic, Z. Markovic, M. Sumarac-Dumanovic, V. Starcevic, D. Micic, V. Trajkovic, Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. Cell. Mol. Life Sci. 64, 1290–1302 (2007)
28. Z. Yuan, K. Cao, C. Lin, L. Li, H.-y. Liu, X.-y. Zhao, L. Liu, H.-x. Deng, J. Li, C.-I. Nie, Y.-Q. Wei, The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1. Mol. Med. 17, 1262–1274 (2011)
29. Y. Zhuang, W.K. Miskimins, Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J. Mol. Signal. 3, 18 (2008)
30. H. Takane, E. Shikata, K. Otsubo, S. Higuchi, I. Ieiri, Polymorphism in human organic cation transporters and metformin action. Pharmacogenomics 9, 415–422 (2008)
31. L.-W. Wang, Z.-S. Li, D.-W. Zou, Z.-D. Jin, J. Gao, G.-M. Xu, Metformin induces apoptosis of pancreatic cancer cells. World J. Gastroenterol. 14, 7192–7198 (2008)
32. B. Martin-Castillo, A. Vazquez-Martin, C. Oliveras-Ferraros, J.A. Menendez, Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle 9, 1057–1064 (2010)
33. M.R. Owen, E. Doran, A.P. Halestrap, Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 348, 607–614 (2000)